CAJ | 학술논문

移植受者长期免疫抑制明显增加感染性疾病及恶性肿瘤的发生概率,且免疫抑制剂无法阻止或延缓慢性移植物排斥反应的发生.间充质干细胞(MSC)兼有免疫抑制能力及诱导免疫耐受的特性.MSC联用免疫抑制剂旨在通过低剂量免疫抑制剂来维持有效的免疫抑制作用,确保MSC输注后不发生排斥反应,同时减少了免疫抑制剂的副作用；利用MSC具有诱导免疫耐受的特性,在特异性耐受形成后安全撤除免疫抑制剂,实现移植物及受者的长期存活.临床最理想的结果是两者协同发挥作用.本文就上述内容进行了文献综述.
이식수자장기면역억제명현증가감염성질병급악성종류적발생개솔,차면역억제제무법조지혹연완만성이식물배척반응적발생.간충질간세포(MSC)겸유면역억제능력급유도면역내수적특성.MSC련용면역억제제지재통과저제량면역억제제래유지유효적면역억제작용,학보MSC수주후불발생배척반응,동시감소료면역억제제적부작용；이용MSC구유유도면역내수적특성,재특이성내수형성후안전철제면역억제제,실현이식물급수자적장기존활.림상최이상적결과시량자협동발휘작용.본문취상술내용진행료문헌종술.
Long-term immunosuppression in recipients markedly increases the morbidity of infectous disease and malignancy,and immunosuppressants fail to prevent or delay chronic graft rejection.Mesenchymal stem cells (MSC) display the property of immunosuppression and induction of immune tolerance.Combined use of MSC and immunosuppressants reduces the risk of acute rejection induced by MSC infusion,and side effects of immunosuppressants when applied alone.After the establishment of specific tolerance by MSC,patients can be weaned off immunosuppressants safely,thus achieving long-term survival of both graft and recipient.Synergistic effect between MSC and immunosuppressive gents is optimal in clinical practice.Herein the advances concerning this aspect are summarized.